What is Insight Molecular Diagnostics Inc.'s market cap?

Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $156.6M and trades on NASDAQ.

What is Insight Molecular Diagnostics Inc.'s revenue and profitability?

Insight Molecular Diagnostics Inc. generated $1.9M in trailing twelve-month revenue with a net loss of $47.8M, representing a net margin of -2454.6%. Gross margin stands at 51.3%, with free cash flow of -$27.5M. These figures are based on the Q1 2026 filing.

Who are Insight Molecular Diagnostics Inc.'s competitors?

Insight Molecular Diagnostics Inc.'s key competitors include CareDx, Inc., Guardant Health, Inc., Natera, Inc., and others. These companies compete in similar markets and product categories.

Who does Insight Molecular Diagnostics Inc. partner with?

Insight Molecular Diagnostics Inc.'s notable partners include Bio-Rad Laboratories, Inc..

What subsidiaries does Insight Molecular Diagnostics Inc. have?

Insight Molecular Diagnostics Inc.'s subsidiaries include Insight Genetics, Inc., Chronix Biomedical, Inc..

Where is Insight Molecular Diagnostics Inc. headquartered?

Insight Molecular Diagnostics Inc. is headquartered in United States of America and employs approximately 49 people. It has been publicly traded since 2015.

Insight Molecular Diagnostics Inc.

IMDX

Insight Molecular Diagnostics is a pioneering diagnostics technology company focused on expanding access to molecular diagnostic testing through a decentralized, kitted-product model.

Market cap

$156.61M+80.7%

Revenue$1.9M-49.3%

Net income-$47.8M+17.8%

Free cash flow-$27.5M-16.9%

EPS (diluted)-$1.50+61.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$32.0KMiss by $197.2K EPS-$0.28Miss by $0.02

Read the full report

Next report

Aug 10, 2026 (In 4 weeks)

Revenue estimate$437.5K

EPS estimate-$0.24

Financials

Q1 2026

Income statement

See full

Revenue$32.0K-98.5%

Gross profit$15.0K-98.9%

Operating income-$4.4M+35.1%

Net income-$4.3M+35.7%

EPS (diluted)-$0.12+53.8%

Balance sheet

See full

Cash & equivalents$28.2M-9.1%

Total debt$2.9M-13.5%

Total equity-$10.7M-205%

Total assets$40.4M-33.0%

Cash flow

See full

Operating cash flow-$7.6M-30.8%

CapEx$613.0K+99.7%

Free cash flow-$8.3M-34.3%

Valuation & ratios

Valuation

See full

Market cap$156.61M+80.7%

Enterprise value$131.3M+100%

P/S80.4×+60.0×

Profitability

See full

Gross margin51.3%-3.0pp

Operating margin-2,500.7%+4,459pp

Net margin-2,454.6%+4,017pp

FCF margin-1,409.7%-6,023pp

Returns & leverage

See full

Current ratio2.5×-1.2×

Competitors

By market cap

Natera, Inc.$40.4B+86.3%

Agilent Technologies$37.7B+11.4%

Guardant Health$21.8B+254%

Bio-Rad Laboratories$8.0B+18.3%

CareDx$1.5B+46.4%

Fulgent Genetics, Inc.$593.0M+1.0%

Insight Molecular Diagnostics Inc.$156.6M+80.7%

ADV

Advanced Biomed Inc. Common Stock$8.8M-38.8%

By revenue growth

Guardant Health+39.6%

Natera, Inc.+36.6%

CareDx+19.2%

Fulgent Genetics, Inc.+9.5%

Agilent Technologies+9.1%

Bio-Rad Laboratories+1.9%

Insight Molecular Diagnostics Inc.-49.3%

By net margin

Agilent Technologies19.55%+2.0pp

Bio-Rad Laboratories6.52%+91.7pp

CareDx-1.98%-19.9pp

Natera, Inc.-14.61%-3.2pp

Fulgent Genetics, Inc.-23.04%-9.1pp

Guardant Health-40.1%+13.7pp

Insight Molecular Diagnostics Inc.-2,454.64%-940pp

Profile

Insight Molecular Diagnostics is a pioneering diagnostics technology company focused on expanding access to molecular diagnostic testing through a decentralized, kitted-product model. The company develops molecular diagnostic test kits that allow hospitals and transplant centers to perform testing in-house, counter-positioning against the traditional centralized laboratory model. Its primary value proposition lies in improving patient care standards and operational sustainability for healthcare institutions through faster turnaround times and localized testing capabilities.

Competitive position

A disruptive challenger in the transplant diagnostics market, utilizing a decentralized kitting model to compete against established centralized laboratory providers.

GeographiesUnited States, Germany, European Union

Customer segmentsHospitals, Transplant Centers, Research Institutions, Biotechnology Companies

Business modelKitted product sales, Laboratory-developed tests (LDT), Service-based revenue

SuppliersDigital PCR instrument manufacturers, Chemical reagent suppliers, Specimen collection service providers

CustomersTransplant surgeons, Nephrologists, Pathologists, Hospital lab managers, Reference laboratories

CountryUnited States of America

Listed2015

Employees49.0

CEOJoshua Riggs

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websiteimdxinc.com

FilingsSEC EDGAR

Ask your AI about Insight Molecular Diagnostics Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insight Molecular Diagnostics Inc.'s market cap?: Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $156.6M and trades on NASDAQ.
What is Insight Molecular Diagnostics Inc.'s revenue and profitability?: Insight Molecular Diagnostics Inc. generated $1.9M in trailing twelve-month revenue with a net loss of $47.8M, representing a net margin of -2454.6%. Gross margin stands at 51.3%, with free cash flow of -$27.5M. These figures are based on the Q1 2026 filing.
Who are Insight Molecular Diagnostics Inc.'s competitors?: Insight Molecular Diagnostics Inc.'s key competitors include CareDx, Inc., Guardant Health, Inc., Natera, Inc., and others. These companies compete in similar markets and product categories.
Who does Insight Molecular Diagnostics Inc. partner with?: Insight Molecular Diagnostics Inc.'s notable partners include Bio-Rad Laboratories, Inc..
What subsidiaries does Insight Molecular Diagnostics Inc. have?: Insight Molecular Diagnostics Inc.'s subsidiaries include Insight Genetics, Inc., Chronix Biomedical, Inc..
Where is Insight Molecular Diagnostics Inc. headquartered?: Insight Molecular Diagnostics Inc. is headquartered in United States of America and employs approximately 49 people. It has been publicly traded since 2015.